- $8.40bn
- $7.42bn
- $285.14m
- 65
- 10
- 43
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.71 | ||
| Price to Tang. Book | 6.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -32.35% | ||
| Return on Equity | -51.94% | ||
| Operating Margin | -185.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 59.98 | 75 | 68.83 | 117 | 285.14 | 580.83 | 1,083.71 | 42.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Directors
- Ye Wang NEC (52)
- Huang Ying CEO (48)
- Meeta Chatterjee SVP (66)
- Lori Macomber VFN (50)
- Li Zhu DRC (71)
- Patrick Casey IND (64)
- Xiaohui Ji IND (59)
- Corazon Sanders IND (64)
- Wai Man Yau IND (44)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 1st, 1970
- Public Since
- June 4th, 2020
- No. of Employees
- 1,800
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 363,822,069
- Address
- 2101 Cottontail Lane, SOMERSET, 08873
- Web
- https://investors.legendbiotech.com/
- Phone
- +1 7323175050
- Auditors
- Ernst & Young Hua Ming LLP
Upcoming Events for LEGN
Q1 2024 Legend Biotech Corp Earnings Release
Q2 2024 Legend Biotech Corp Earnings Release
Legend Biotech Corp Annual Shareholders Meeting
Similar to LEGN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Legend Biotech share price?
As of Today at 19:13 UTC, shares in Legend Biotech are trading at $46.19. This share price information is delayed by 15 minutes.
How has the Legend Biotech share price performed this year?
Shares in Legend Biotech last closed at $46.19 and the price had moved by -27.55% over the past 365 days. In terms of relative price strength the Legend Biotech share price has underperformed the S&P500 Index by -39.71% over the past year.
What are the analyst and broker recommendations for Legend Biotech?
The overall consensus recommendation for Legend Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Legend Biotech dividend yield?
Legend Biotech does not currently pay a dividend.
Does Legend Biotech pay a dividend?
Legend Biotech does not currently pay a dividend.
When does Legend Biotech next pay dividends?
Legend Biotech does not currently pay a dividend.
How do I buy Legend Biotech shares?
To buy shares in Legend Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Legend Biotech?
As of the previous close price of $46.19, shares in Legend Biotech had a market capitalisation of $8.40bn.
Where are Legend Biotech shares listed?
Here are the trading details for Legend Biotech:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LEGN
What kind of share is Legend Biotech?
Based on an overall assessment of its quality, value and momentum Legend Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Legend Biotech share price forecast for 2024?
The analyst consensus target price for shares in Legend Biotech is $86.16. That is 86.53% above the last closing price of $46.19.
Analysts covering Legend Biotech currently have a consensus Earnings Per Share (EPS) forecast of -$1.47 for the next financial year.
What is the trend in the Legend Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Legend Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -41.07%.
As of the last closing price of $46.19, shares in Legend Biotech were trading -27.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Legend Biotech PE Ratio?
The Legend Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $46.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Legend Biotech?
Legend Biotech's management team is headed by:
- Ye Wang - NEC
- Huang Ying - CEO
- Meeta Chatterjee - SVP
- Lori Macomber - VFN
- Li Zhu - DRC
- Patrick Casey - IND
- Xiaohui Ji - IND
- Corazon Sanders - IND
- Wai Man Yau - IND